Alembic Pharmaceuticals Ltd.

Financial

	Alembic Pharma	Ipca Laboratories	JB Chem & Pharma
Operational Metrics
API Sector
US DMF Filings	132.0 .	55.0 .	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	260.0 .	44.0 .	19.0 .
Number of ANDA's Approved By USFDA	197.0 .	18.0 .	17.0 .
Number of ANDA's Filed in Latam	14.0	n/a	n/a
Number of ANDA's Approved by Latam	4.0	n/a	n/a
Number of ANDA's Filed in South Africa	21.0	n/a	n/a
Number of ANDA's Approved by South Africa	7.0	n/a	n/a
Number of ANDA's Filed in Australia	17.0	n/a	n/a
Number of ANDA's Approved by Australia	14.0	n/a	n/a
Number of ANDA's Filed in Canada	21.0	n/a	n/a
Number of ANDA's Approved by Canada	20.0	n/a	n/a
Number of ANDA's Filed in Europe	21.0	n/a	n/a
Number of ANDA's Approved in Europe	19.0	n/a	n/a
R&D as a % of Total Sales	8.0 %	2.71 %	1.55 %
Financials
5 yr Average ROE	15.79 %	15.9 %	18.27 %
5yr average Equity Multiplier	1.48	1.41	1.5
5yr Average Asset Turnover Ratio	0.83	0.81	0.79
5yr Avg Net Profit Margin	13.0 %	13.8 %	15.59 %
Price to Book	3.88	4.63	9.57
P/E	30.32	53.6	50.65
5yr Avg Cash Conversion Cycle	1.45 Days	74.74 Days	37.72 Days
Inventory Days	94.67 Days	100.02 Days	52.43 Days
Days Receivable	60.69 Days	55.52 Days	63.16 Days
Days Payable	176.63 Days	120.62 Days	81.2 Days
5yr Average Interest Coverage Ratio	36.16	59.4	74.05
5yr Avg ROCE	17.34 %	18.97 %	22.31 %
5yr Avg Operating Profit Margin	20.24 %	22.38 %	24.93 %
5 yr average Debt to Equity	0.2	0.14	0.06
5yr CAGR Net Profit	-5.77 %	1.13 %	16.2 %
5yr Average Return on Assets	10.48 %	11.44 %	12.35 %
Shareholdings
Promoter Holding	69.61 %	46.3 %	53.78 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.13 %	0.01 %	-2.13 %
Change in Mutual Fund Holding (3 Yrs)	3.48 %	7.98 %	4.89 %

Business

	Alembic Pharma	Ipca Laboratories	JB Chem & Pharma
Product Wise Break-Up	Product Wise Break-Up Formulations 78.25 Active Pharmaceutical Ingredient (API) 21.75 Generics 0 Branded Generics 0 Contract Manufacturing 0 Formulation exported 0 Domestic formulation 0	Product Wise Break-Up Formulations 0 Formulations 21.36 Active Pharmaceutical Ingredient (API) 0 Branded Generics 54.13 Formulation exported 0 Domestic formulation 0 Contract Manufacturing 0 Others 24.51	Product Wise Break-Up Formulations 0 Generics 0 Active Pharmaceutical Ingredient (API) 0 Branded Generics 0 Formulations 30.97 Domestic Formulations 53.94 Contract Manufacturing 12.65 Others 2.44
Product Wise Break-Up	Product Wise Break-Up Formulations 78.25 Active Pharmaceutical Ingredient (API) 21.75 Generics 0 Branded Generics 0 Contract Manufacturing 0 Formulation exported 0 Domestic formulation 0	Product Wise Break-Up Formulations 0 Formulations 21.36 Active Pharmaceutical Ingredient (API) 0 Branded Generics 54.13 Formulation exported 0 Domestic formulation 0 Contract Manufacturing 0 Others 24.51	Product Wise Break-Up Formulations 0 Generics 0 Active Pharmaceutical Ingredient (API) 0 Branded Generics 0 Formulations 30.97 Domestic Formulations 53.94 Contract Manufacturing 12.65 Others 2.44
Location Wise Break-Up	Location Wise Break-Up Rest of the World 60.12 India 39.88 Australia 0 CIS 0 Asia 0 USA 0 Africa 0 Europe 0 Russia 0 South Africa 0	Location Wise Break-Up India 52.01 South Africa 0 CIS 3.56 Australia 4.47 Africa 7.68 USA 10.26 Asia Pacific 7.87 Europe 14.15 Rest of the World 0 Russia 0	Location Wise Break-Up India 52.06 South Africa 0 CIS 0 Australia 0 Africa 0 USA 0 Asia 0 Europe 0 Rest of the World 47.94 Russia 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Nutraceuticals 0 Urology 0 Dermatology 0 Cough 0 Neuro 0 GI 0 Anti Malarials 0 Cardiovascular & Anti Diabetics 0 NSAID 0 Others 100	Therapeutic Area Break-Up Anti Malarials 24.0 Dermatology 0 Cough 2.0 Cardiovascular & Anti Diabetics 25.0 Urology 0 Neuro 7.0 NSAID 21.0 GI 6.0 Nutraceuticals 0 Others 15.0	-

Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

SIGN UP FOR FREE